First AI-Designed Phage Given to Human Patient

California startup Radical Numerics said a patient with a serious bacterial infection received a phage treatment designed by its AI model Omnii-1, the first reported human use of AI-designed phages, delivered via an expanded-access program. The announcement is unreviewed by peers, and the company has not disclosed the patient's diagnosis or outcome, though the mixture cleared the patient's resistant bacterial sample in lab tests.

3 effects · 2 potentially affected companies · The full cascade analysis is part of the Pro plan. Create free account

This is a proof-of-concept milestone for generative biology applied to antimicrobial resistance, moving AI-designed organisms from lab experiments to a human patient. The evidence is thin, since it rests on a company announcement with no peer review and no clinical outcome. It nonetheless strengthens the case for AI-driven biological design platforms and may attract investor and partner interest to AI-phage startups. Regulators will likely need to define pathways for patient-specific, AI-engineered biologics, and biosecurity concerns about AI-designed viruses will likely get more attention. Large pharma and antibiotic developers are unlikely to see near-term financial effects until efficacy data arrive.